Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer

Details for Australian Patent Application No. 2005211764 (hide)

Owner University of Virginia Patent Foundation

Inventors MacDonald, Timothy L.; Gray, Lloyd S.

Agent Davies Collison Cave

Pub. Number AU-B-2005211764

PCT Pub. Number WO2005/077082

Priority 60/543,756 11.02.04 US

Filing date 11 February 2005

Wipo publication date 25 August 2005

Acceptance publication date 21 July 2011

International Classifications

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 31/4184 (2006.01)

A61K 31/4422 (2006.01) - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 49/00 (2006.01) Preparations for testing

A61P 35/00 (2006.01) Antineoplastic agents

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

G01N 33/53 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

31 August 2006 PCT application entered the National Phase

  PCT publication WO2005/077082 Priority application(s): WO2005/077082

21 July 2011 Application Accepted

  Published as AU-B-2005211764

17 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005211773-Nicotinamide riboside kinase compositions and methods for using the same

2005211762-Buyer initiated payment